News
Lilly’s results from an obesity pill study didn’t perform as well as Wall Street expected. It resulted in lower weight loss ...
In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 ...
Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 ...
In a clinical trial, the company's weight loss pill resulted in a nearly 12% weight loss at 72 weeks for participants who took the highest dose of the medication. On average, participants lost 7.8% to ...
Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight ...
A series of lawsuits have been filed in Marion County court alleging that drug manufacturer Eli Lilly downplayed the side ...
Shares of Eli Lilly plunged after the drug maker reported less-than-stellar results of a new study of an experimental anti-obesity pill that is expected to become a blockbuster. The pill helped people ...
Flutter Entertainment Posts Higher Second-Quarter Revenue Amid FanDuel Purchase The betting company posted $4.19 billion in revenue, beating analyst expectations. The Las Vegas operator of casinos and ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...
Eli Lilly stock crashes as late-stage data for weight-loss pill falls short of expectations. Analyst explains why data wasn't ...
Eli Lilly’s LLY 38% revenue growth and 61% non-GAAP EPS growth in the second quarter were above consensus expectations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results